Press release
Rising HIV Infections Driving Growth In HIV Clinical Trials Market Due To Increasing Disease Burden And Need For Effective Treatments: Strategic Insights Driving Human Immunodeficiency Viruses (HIV) Clinical Trials Market Momentum in 2025
Human Immunodeficiency Viruses HIV Clinical Trials Market
How Large Will the Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size By 2025?
In recent times, there has been significant growth experienced by the market of clinical trials for human immunodeficiency viruses (HIV). This market, which was valued at $1.77 billion in 2024, is projected to increase to $1.94 billion in 2025, marking a compound annual growth rate (CAGR) of 9.3%. The historic growth can be linked to factors including the rising incidence of drug-resistant strains of human immunodeficiency viruses, the growing call for personalized medicine in HIV care, emphasis on early detection and treatment, an increased count of clinical research organizations, and heightened awareness about HIV-related comorbidities.
How Big Is the Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Expected to Grow by 2029?
The market size for clinical trials focused on human immunodeficiency viruses (HIV) is projected to experience significant expansion in the upcoming years. By 2029, it's expected to reach a valuation of $2.73 billion, with a compound annual growth rate (CAGR) of 9.0%. The predicted growth within this period can be linked to factors such as a higher incidence of HIV infections, heightened awareness about HIV prevention and treatment strategies, a surge in the adoption of antiretroviral therapy, increased government funding for HIV research, and enhanced investment in biotechnology and pharmaceutical sectors. The forecast period will also witness notable trends like technological innovations in HIV diagnostic procedures, progress in antiretroviral therapy (ART) formulas, advancements in identifying biomarkers, the use of technology in remote patient monitoring solutions, and the amalgamation of digital health platforms.
View the full report here:
https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-viruses-hiv-clinical-trials-global-market-report
Which Key Market Drivers Powering Human Immunodeficiency Viruses (HIV) Clinical Trials Market Expansion and Growth?
The surge in human immunodeficiency virus (HIV) infections is anticipated to drive the expansion of the HIV clinical trials market. HIV infections denote the situation where the HIV virus attacks and weakens the immune system, heightening the vulnerability to infections and potentially leading to AIDS. The infection rise can largely be attributed to the lack of awareness about its transmission, leading to risky behaviour and delayed testing that enables the spreading of the virus. HIV clinical trials provide a ray of hope for HIV patients by testing new medications, vaccines, and treatment methodologies to refine prevention, better manage the virus, and eventually slow down disease progression and transmission. For example, as per the Minority HIV/AIDS Fund (MHAF), a government agency based in the US, there were around 39.9 million individuals globally living with HIV in 2023, which included 38.6 million adults and 1.4 million children, a significant increase from previous years. Therefore, the escalating incidence of HIV infections is fueling the expansion of the HIV clinical trials market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28244&type=smp
Which Fast-Growing Trends Are Poised to Disrupt the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
Leading firms in the market for clinical trials for the human immunodeficiency virus (HIV) are concentrating on creating cutting-edge solutions such as injections for HIV prevention to boost the effectiveness of treatments and lower transmission rates. A preventative HIV injection is a long-acting injectable form of medication given on a scheduled basis to prevent infection with HIV in those at high risk by inhibiting the virus from causing infection in the body. For example, in August 2025, Gilead Sciences Inc., a pharmaceutical company based in the US, was granted approval by the European Union for a drug called Yeytuo (lenacapavir) to treat HIV. This drug is administered twice a year as an HIV preventative measure, has been shown in clinical trials to be nearly 100% effective and substantially decreases the chance of sexually contracted HIV-1. Its long-lasting dosage cycle makes it more convenient and easier to adhere to than the daily oral PrEP, addressing a significant shortfall in HIV prevention. It is intended for adolescents and adults who are at increased risk, with a goal of broadening access and contributing to a reduction in new HIV infection rates globally as part of extensive prevention strategies.
What Are the Emerging Segments in the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
The human immunodeficiency viruses (HIV) clinical trials market covered in this report is segmented as
1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical
2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations
5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies
2) By Phase Ii: Dose-Finding Studies, Efficacy Studies
3) By Phase Iii: Pivotal Trials, Comparative Efficacy Studies
4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies
5) By Preclinical: In Vitro Studies, Animal Studies
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28244&type=smp
Who Are the Global Leaders in the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio.
Which are the Top Profitable Regional Markets for the Human Immunodeficiency Viruses (HIV) Clinical Trials Industry?
North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human immunodeficiency virus (HIV) clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28244
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising HIV Infections Driving Growth In HIV Clinical Trials Market Due To Increasing Disease Burden And Need For Effective Treatments: Strategic Insights Driving Human Immunodeficiency Viruses (HIV) Clinical Trials Market Momentum in 2025 here
News-ID: 4213248 • Views: …
More Releases from The Business Research Company
Competitive Analysis: Leading Companies and New Entrants in the Wire Arc Additiv …
The wire arc additive manufacturing cell market is rapidly gaining traction as industries increasingly embrace advanced metal 3D printing technologies. With significant investments and technological breakthroughs, this sector is set to experience remarkable growth, transforming manufacturing processes across multiple fields. Let's explore the market's size, influential players, key trends, and segmentation to understand its future trajectory.
Projected Expansion of the Wire Arc Additive Manufacturing Cell Market
The wire arc additive manufacturing cell…
Future Perspectives: Key Trends Shaping the Viscosupplementation Treatment for A …
The viscosupplementation treatment for arthritis market is on the verge of significant expansion, driven by advances in medical technology and a growing demand for effective arthritis therapies. With increasing awareness around early intervention and new treatment options, this sector is poised for rapid development over the coming years. Let's explore the market size, key players, emerging trends, and segment-wise forecasts that define this growing industry.
Projected Market Growth and Size of…
Segmentation, Major Trends, and Competitive Overview of the Viral Vector Develop …
The viral vector development service market is set to experience substantial growth in the coming years, driven by technological progress and increasing demand from various sectors. As gene therapies and advanced treatments gain prominence, the need for efficient viral vector production and development is becoming more critical. Let's explore the market size projections, key players, emerging trends, and the segment structure shaping this industry's future.
Projected Expansion and Market Size of…
Competitive Landscape: Leading Companies and New Entrants in the Transient Elast …
The transient elastography market is poised for substantial expansion as advancements in healthcare diagnostics continue to evolve. Increasing emphasis on non-invasive techniques and early disease detection is driving widespread adoption, setting the stage for strong market growth in the coming years. Let's explore the current market valuation, leading players, emerging innovations, and key segments shaping this industry.
Projected Market Value and Growth of the Transient Elastography Market
The transient elastography market is…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
